Isosorbide Dinitrate/Mononitrate (Monograph)
Brand names: Dilatrate, Imdur, Ismo, Isordil, Monoket
Drug class: beta-Adrenergic Blocking Agents
VA class: CV250
Introduction
Isosorbide dinitrate and isosorbide mononitrate: Organic nitrates; vasodilating agents.
Uses for Isosorbide Dinitrate/Mononitrate
Angina
Isosorbide dinitrate or mononitrate is used for the acute relief of angina pectoris, for prophylactic management in situations likely to provoke angina attacks, and for long-term prophylactic management of angina pectoris.b
Conventional measures in the management of angina pectoris are aimed at reducing the frequency, duration, and severity of attacks, and include coronary risk reduction (e.g., discontinuance of smoking, weight control, antilipemic strategies), rest, avoidance of precipitating circumstances (e.g., eating heavy meals, getting emotionally upset, performing strenuous exercise, exposure to cold air) and, if possible, treatment of the underlying cause.c
β-Adrenergic blocking agents (β-blockers) generally are considered among the initial antianginal drugs of choice in the long-term prophylactic management of chronic stable angina with or without prior MI to reduce symptoms and to prevent MI and/or death.258 c
Isosorbide dinitrate or mononitrate can be used alone or in combination as either second-line or third-line therapy in patients previously treated with a β-blocker.258
Prolonged use of oral nitrates has been associated with the development of tolerance to the hemodynamic and antianginal effects and possibly with cross-tolerance to sublingual nitrates. (See Tolerance and Dependence under Cautions.)
Generally considered for monotherapy in the prophylactic management of angina pectoris only when β-blockers or calcium-channel blocking agents are contraindicated, associated with unacceptable adverse effects, or are ineffective.258
If a β-blocker is not effective in controlling chronic stable angina, long-acting nitrates may be added to β-blocker therapy.258
Heart Failure
Isosorbide dinitrate used in fixed combination with hydralazine (BiDil) as adjunct to standard therapy for the treatment of heart failure in self-identified black patients to improve survival, decrease rate of hospitalization for worsened heart failure, and improve patient-reported functional status.336 337 338 524
Current guidelines recommend a combination of drug therapies (e.g., ACE inhibitors, angiotensin II receptor antagonists, angiotensin receptor-neprilysin inhibitors [ARNIs], β-blockers, aldosterone receptor antagonists) in adults with heart failure to reduce morbidity and mortality.524 700 701 703
Combination of isosorbide dinitrate and hydralazine recommended by ACCF and AHA for self-identified black patients with NYHA class III or IV heart failure and reduced ejection fraction who are receiving optimal therapy with ACE inhibitors and β-blockers, unless contraindicated.524
ACCF and AHA state that combined therapy with isosorbide dinitrate and hydralazine also can be useful in patients with current or prior symptomatic heart failure with reduced ejection fraction who cannot receive an ACE inhibitor or angiotensin II receptor antagonist† [off-label] because of drug intolerance, hypotension, or renal insufficiency.524
Diffuse Esophageal Spasm
Isosorbide dinitrate has been used effectively for diffuse esophageal spasm† [off-label] without gastroesophageal reflux to relieve pain, dysphagia, and spasm.b
Isosorbide Dinitrate/Mononitrate Dosage and Administration
Administration
Isosorbide Dinitrate
Administer sublingually, intrabuccally, or orally.b
Sublingual or intrabuccal nitrates may be inadequately absorbed, with resultant decreased efficacy, in patients with dry oral mucous membranes (e.g., xerostomia).219 220
Do not chew extended-release preparations.b
The patient should be sitting immediately after sublingual or intrabuccal administration.b
Isosorbide Mononitrate
Extended-release tablets can be administered as whole or halved tablets, but swallow intact and do not chew or crush.292
Administer extended-release tablets with adequate amounts of fluid (e.g., 120 mL) on arising in the morning.292
Dosage
Adjust dosage of isosorbide dinitrate and isosorbide mononitrate carefully according to the patient’s requirements and response; use the smallest effective dosage.b
Although many clinicians do not gradually reduce the dosage when discontinuance of oral nitrates is planned, it appears prudent that dosage be gradually reduced (e.g., over a period of about 1–2 weeks) to avoid withdrawal manifestations.c Supplementary sublingual nitroglycerin doses should be given if necessary during dosage reduction.302
Adults
Angina
Acute Symptomatic Relief and Prophylactic Management
Do not use extended-release isosorbide dinitrate preparations or any isosorbide mononitrate preparation to abort an acute anginal episode or for acute relief of angina or in the prophylactic management in situations likely to provoke angina attacks; onset is not sufficiently rapid.224 290 291 292
SublingualPatients who fail to respond to nitroglycerin lingual or sublingual: 2.5–5 mg of isosorbide dinitrate.b
If relief is not attained after a single dose during an acute attack, may give additional doses at 5- to 10-minute intervals; give no more than 3 doses in a 15- to 30-minute period.b
Prophylactic management in situations likely to provoke angina attacks in patients who fail to respond to sublingual nitroglycerin: place 2.5–5 mg of isosorbide dinitrate under the tongue about 15 minutes prior to engaging in such activities.200
IntrabuccalPatients who fail to respond to nitroglycerin lingual or sublingual: 2.5–5 mg of isosorbide dinitrate.b
If relief is not attained after a single dose during an acute attack, may give additional doses at 5- to 10-minute intervals; no more than 3 doses should be given in a 15- to 30-minute period.b
Prophylactic management in situations likely to provoke angina attacks in patients who fail to respond to sublingual nitroglycerin: 2.5–5 mg of isosorbide dinitrate should be placed under the tongue approximately 15 minutes prior to engaging in such activities.200
Long-term Prophylactic Management
Oral (Isosorbide Dinitrate Conventional Tablets)Initially, isosorbide dinitrate conventional tablets (e.g., Isordil Titradose) 5–20 mg administered 2–3 times daily, followed by maintenance dosage of 10–40 mg administered 2–3 times daily (some patients may require higher dosages).302 b
Suggested schedules: Usually, at 7 a.m., 12 p.m., and 5 p.m. in chronic stable angina or at 7 a.m. and 12 p.m. in less severely symptomatic angina in order to allow for a nitrate-free interval of 10–14 hours.302 b
May need to adjust schedule for those arising earlier than 7 a.m. since early morning angina is common.324
Less frequent administration of isosorbide dinitrate may reduce the development of tolerance to the drug’s antianginal effects.b c
Oral (Isosorbide Dinitrate Extended-release Capsules)An interdosing interval sufficient to avoid tolerance to Dilatrate-SR extended-release capsules is not known, but it must exceed 18 hours.224
Do not exceed daily Dilatrate-SR dosages of 160 mg (4 capsules).224
Oral (Isosorbide Mononitrate Conventional Tablets)Usual initial dosage of conventional tablets (e.g., Monoket): 20 mg twice daily, with the 2 doses administered 7 hours apart.290 291
Particularly small stature, initially: 5 mg (½ of a 10-mg tablet) twice daily, for no longer than initial 2 days.291
Particularly small stature, maintenance: Increased to at least 10 mg twice daily by the second or third day.291
Oral (Isosorbide Mononitrate Extended-release Tablets)Initially, (e.g., Imdur): 30 mg (as a single 30-mg tablet or as ½ of a 60-mg tablet) or 60 mg (as a single 60-mg tablet) once daily.292
May increase dosage to 120 mg (as a single 120-mg tablet or as two 60-mg tablets) once daily after several days; 240-mg dosages rarely needed.292
Heart Failure
Fixed-combination Therapy with Hydralazine in Self-identified Black Patients
OralInitially, isosorbide dinitrate 20 mg and hydralazine hydrochloride 37.5 mg (1 tablet of BiDil) 3 times daily.336 524 May titrate dosage to a maximum tolerated dosage not to exceed 2 tablets (a total of 40 mg of isosorbide dinitrate and 75 mg of hydralazine hydrochloride) 3 times daily.336 524 Rapid titration (over 3–5 days) may be possible; however, slower titration may be needed due to adverse effects.336 May decrease dosage to as little as ½ of the fixed-combination tablet 3 times daily in patients who experience intolerable effects, but attempt to titrate dosage up once adverse effects subside.336
Isosorbide Dinitrate Therapy† [off-label]
Oral (Isosorbide Dinitrate Conventional Tablets)ACCF and AHA recommend initial dosage of 20–30 mg 3 or 4 times daily; give concomitantly with hydralazine hydrochloride 25–50 mg 3 or 4 times daily.524 Titrate dosages to levels similar to those recommended for the fixed-combination preparation and administer both drugs at least 3 times daily.524
Diffuse Esophageal Spasm
Oral (Isosorbide Dinitrate Conventional Tablets)
10–30 mg 4 times daily.b
Prescribing Limits
Adults
Angina
Acute Symptomatic Relief and Prophylactic Management
SublingualNo more than 3 doses in a 15- to 30-minute period.b
IntrabuccalNo more than 3 doses in a 15- to 30-minute period.b
Long-term Prophylactic Management
Oral (Isosorbide Dinitrate Extended-release Capsules)Maximum daily dosage of Dilatrate-SR: 160 mg (4 capsules).224
Oral (Isosorbide Mononitrate Extended-release Tablets)Dosages of 240 mg are rarely needed.292
Heart Failure
Fixed-combination Therapy with Hydralazine in Self-identified Black Patients
OralMaximum 40 mg of isosorbide dinitrate and 75 mg of hydralazine hydrochloride (2 tablets of BiDil) 3 times daily.336
Isosorbide Dinitrate Therapy† [off-label]
Oral (Isosorbide Dinitrate Conventional Tablets)Maximum 120 mg daily administered concomitantly with hydralazine hydrochloride (maximum 300 mg daily).524
Special Populations
Hepatic Impairment
No specific dosage recommendations for hepatic impairment.b
Renal Impairment
No specific dosage recommendations for renal impairment.b
Geriatric Patients
One manufacturer of isosorbide mononitrate states that dosage should be selected with caution, usually initiating therapy at the low end of the range, although age, renal, hepatic, and cardiovascular dysfunction do not appear to have a significant effect on drug clearance.325
The manufacturer of the fixed combination of isosorbide dinitrate and hydralazine hydrochloride states that dosage should be selected with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.336
Cautions for Isosorbide Dinitrate/Mononitrate
Contraindications
-
Known hypersensitivity to isosorbide or any ingredient in the respective formulation.302
-
Manufacturers state that selective phosphodiesterase (PDE) inhibitors (e.g., sildenafil, tadalafil, vardenafil) are contraindicated in patients receiving nitrates.c Complete avoidance may not be possible, provided sufficient time elapses between use of the drugs.c (See Selective Phosphodiesterase (PDE) Inhibitors under Cautions.)
-
Extended-release oral nitrate preparations should not be used in patients with functional or organic GI hypermotility or malabsorption syndrome.c
-
Isosorbide dinitrate is contraindicated in patients with shock or marked low blood pressure.c
Warnings/Precautions
Warnings
Selective Phosphodiesterase (PDE) Inhibitors
Selective PDE inhibitors can potentiate the hypotensive effects of organic nitrates and nitrites, possibly resulting in potentially life-threatening hypotension and/or hemodynamic compromise.c
Manufacturers of selective PDE inhibitors (e.g., sildenafil, tadalafil, vardenafil) state that the drugs are contraindicated in patients receiving organic nitrates or nitrites in any form (e.g., orally, sublingually, transmucosally, parenterally), given regularly or intermittently,262 or nitric oxide donors since severe, potentially fatal hypotensive episodes can occur.260 261 262 263 266 271 272 282 284 285 288
Clinicians unfamiliar with their patients’ drug history, especially those involved in emergency care (e.g., for presumed myocardial infarction or ischemia), should take a careful history so that concomitant use of organic nitrates or nitrites with selective PDE inhibitors can be avoided.260 264 271
Warn all patients receiving organic nitrates or nitrites about the potential interaction between the drugs and selective PDE inhibitors, even if they currently are not receiving the drugs, since there is substantial potential for patients to receive the drugs from another clinician, from a friend, with little or no clinical intervention (e.g., via the Internet),281 or illicitly.260 281 282
Warn all patients taking either selective PDE inhibitors or organic nitrates or nitrites of the potential consequences of taking the drugs within close proximity (e.g., within 24 hours of sildenafil; possibly more prolonged periods of risk with longer-acting PDE inhibitors) of taking a nitrate- or nitrite-containing preparation.260 282
Cardiovascular Effects
Severe hypotension, particularly in upright position, can occur even with low doses.302
Caution in volume depletion or preexisting hypotension.302
Paradoxical bradycardia and angina exacerbation may accompany hypotension.302
Benefits in acute MI and heart failure not established.302
Careful clinical or hemodynamic monitoring for possible hypotension or tachycardia if used in acute MI or heart failure.302
Avoid long-acting dosage forms in the early management of acute MI or heart failure since the effects are difficult to terminate rapidly should excessive hypotension or tachycardia occur.c
Sensitivity Reactions
Occur extremely rarely.302
General Precautions
Tolerance and Dependence
Tolerance to the vascular and antianginal effects of individual nitrates and cross-tolerance among the drugs may occur with repeated, prolonged use.c
Carefully individualize nitrate dosage to minimize the risk of tolerance; also consider potential risks of nitrate withdrawal.c
Employ intermittent dosing of nitrates (e.g., use of a nitrate-free interval of 10–12 hours daily) to minimize or prevent the development of tolerance to the hemodynamic and antianginal effects of the drugs.c
Possibility of an increased frequency or severity of angina during the nitrate-free interval should be considered.c
Possible cross-tolerance to sublingual nitroglycerin during chronic nitrate use.c
Nitrate dependence is possible (documented in daily industrial exposures); withdrawal manifestations (e.g., ischemic symptoms, MI, sudden death) can occur.c
Use of Fixed Combinations
When isosorbide dinitrate is used in fixed combination with hydralazine, consider the cautions, precautions, and contraindications associated with hydralazine.336
Specific Populations
Pregnancy
Category C.PDH
Lactation
Not known whether isosorbide dinitrate and isosorbide mononitrate are distributed into milk.200 224 290 291 292 302 Caution if used in nursing women.302
Geriatric Use
Not known whether geriatric patients respond differently than younger patients.325 336 (See Geriatric Patients under Dosage.)
Common Adverse Effects
Serious adverse reactions to the organic nitrates and nitrites are uncommon and their adverse effects mainly involve the CNS and cardiovascular system.
Headache, the most frequent adverse effect, may be severe (persistent or transient) and is perceived as a pulsating, throbbing sensation; frequent early in therapy, usually diminishes rapidly, and may disappear within several days to weeks of continuous therapy.c Aspirin or acetaminophen may relieve.c
Postural hypotension may occur and may cause dizziness, weakness, and other signs of cerebral ischemia.
Transient flushing may occur with the nitrates, and inhalation of amyl nitrite commonly causes cutaneous flushing of the head, neck, and clavicular area.
May cause a burning or tingling sensation when administered sublingually.
May cause blurred vision and should be discontinued if this symptom occurs.
Drug Interactions
Specific Drugs or Laboratory Tests
|
Drug or Test |
Interaction |
Comments |
|---|---|---|
|
Alcohol |
Concomitant use may cause hypotensionc |
Use concomitantly with cautionc |
|
Antihypertensive drugs |
Possible additive hypotensive effectsc |
Dosage adjustment of either the nitrate/nitrite or the other agent with hypotensive activity may be necessary to avoid orthostatic hypotension during concomitant usec |
|
Disopyramide |
Disopyramide may reduce the efficacy of isosorbide dinitrate294 Antimuscarinic actions of disopyramide may decrease salivary secretions and thereby inhibit the dissolution of the sublingual tablets294 |
Use concomitantly with caution |
|
Ergot alkaloids (dihydroergotamine) |
Dihydroergotamine may counteract the coronary vasodilatory effect of nitrates303 316 |
Use concomitantly with caution; risk of angina precipitation |
|
Nitrates or Nitrites |
Patients receiving nitrates or nitrites concomitantly should be observed for possible additive hypotensive effectsc |
Dosage adjustment of either the nitrate/nitrite or the other agent with hypotensive activity may be necessary to avoid orthostatic hypotension during concomitant usec |
|
Phenothiazines |
Possible additive hypotensive effectsc |
Use concomitantly with caution; may need to adjust dosage to avoid orthostatic hypotension c |
|
Phosphodiesterase (PDE) inhibitors, selective |
Sildenafil and other selective PDE inhibitors (e.g., tadalafil, vardenafil) profoundly potentiate the vasodilatory effects (e.g., a >25-mm Hg decrease in SBP) of organic nitrates and nitrites (e.g., nitroglycerin, isosorbide dinitrate), and potentially life-threatening hypotension and/or hemodynamic compromise can result259 260 261 262 263 264 266 271 272 274 275 282 284 285 |
Because of the serious risk of concurrent use of organic nitrates or nitrites and selective PDE inhibitors, such combined use is contraindicated259 260 261 262 282 287 If consideration is given to administering a nitrate or nitrite after a PDE inhibitor (e.g., >24 hours after sildenafil use), the response to the initial doses must be monitored carefully and proper facilities for fluid and vasopressor (e.g., α-adrenergic agonists) support must be readily available to prevent acute ischemic episodes260 289 |
|
Test, Zlatkis-Zak color reaction |
Nitrates and nitrites may interfere with the Zlatkis-Zak color reaction causing a false report of decreased serum cholesterolc |
Isosorbide Dinitrate/Mononitrate Pharmacokinetics
Absorption
Bioavailability (Isosorbide Dinitrate)
Readily (and almost completely) absorbed from the GI tract and oral mucosa, but considerable variations in the bioavailability (10–90%) secondary to extensive first-pass metabolism in the liver.224 294 302
Conventional oral tablets: 25% unchanged drug; about half that following sublingual administration (40–50%).20 200 226 228
Bioavailability (Isosorbide Mononitrate)
Readily absorbed from the GI tract;291 294 295 does not undergo first-pass hepatic metabolism.290 291 292 294 295 296 297 298
Conventional tablets: Approximately 100%.b
Extended-release tablets: Approximately 77–80%.290 291 292 294 295 296 297 298
Onset and Duration
The approximate onset and duration of action of various dosage forms of isosorbide dinitrate (ISDN) and isosorbide mononitrate (ISMN) are as follows:b
|
Dosage Form |
Onset |
Duration |
|---|---|---|
|
Sublingual ISDN |
||
|
Chewable ISDN |
Within 3 min225 |
2–2.5 h225 |
|
Oral ISDN |
1 h225 |
Up to 8 h225 |
|
Oral ISMN |
||
|
Extended-release ISDN |
1 h224 |
8 h224 |
|
Extended-release ISMN |
1 h298 |
12 h298 |
|
Dosage Form |
Onset |
Duration |
|---|---|---|
|
Sublingual ISDN |
Within 15–30 min |
1.5–4 h |
|
Chewable ISDN |
5 min |
2–3 h |
|
Oral ISDN |
Within 20–60 min |
4–6 h |
|
Oral ISMN |
10–30 min314 |
At least 6 h314 |
|
Extended-release ISDN |
Within 2 h313 |
Up to 12 h313 |
|
Extended-release ISMN |
20–30 min314 |
At least 6 h314 |
Onset and duration of action following intrabuccal administration are probably similar to those after sublingual administration of isosorbide dinitrate.b
Food
Isosorbide dinitrate: Food may decrease substantially mean peak plasma concentrations, yet total bioavailability does not seem to be affected.299 311 The effect of food on the bioavailability of isosorbide dinitrate when administered in fixed combination with hydralazine hydrochloride is not known.336
Isosorbide mononitrate: Generally, food delays the rate but not the extent of absorption (less than 10%) of conventional or extended-release tablets.292 295 298 299 300 301
Plasma Concentrations
Isosorbide dinitrate – sublingual, peak: 10–15 minutes.200 302
Isosorbide dinitrate – conventional tablets, peak: 60 minutes.200 302
Isosorbide dinitrate – fixed-combination tablets with hydralazine hydrochloride, peak: 60 minutes.336
Isosorbide mononitrate – conventional tablets, peak: 0.5–1 hour.292
Isosorbide mononitrate – extended-release tablets, peak: 3–4.5 hours.292
Special Populations
Risk of elevated blood concentrations of isosorbide dinitrate in patients with cirrhosis.336
Distribution
Extent
Distribution into human body tissues and fluids has not been fully characterized.294 302 303 304
Not known whether isosorbide dinitrate and isosorbide mononitrate are distributed into milk.200 224 290 291 292 302
Plasma Protein Binding
Isosorbide dinitrate: Approximately 28%.290 291 292 303
Isosorbide mononitrate: Approximately 4–5%.290 291 292 303
Elimination
Metabolism
Isosorbide dinitrate: Metabolized extensively; about 15–25 and 75–85% of a dose is metabolized to isosorbide-2-mononitrate and isosorbide-5-mononitrate (referred to simply as isosorbide mononitrate), respectively; 200 224 290 291 292 302 both metabolites are pharmacologically active, especially isosorbide mononitrate.200 224 290 291 292 302
Isosorbide dinitrate: Also probably metabolized at extrahepatic sites.200 224 302
Isosorbide mononitrate: Metabolized principally in the liver, but unlike isosorbide dinitrate, does not undergo first-pass metabolism;290 291 292 metabolites appear to be pharmacologically inactive.291 292
Elimination Route
Isosorbide dinitrate and isosorbide mononitrate are mainly excreted in the urine.b 291
Half-life
Isosorbide dinitrate: About 1 hour.200 224 225 302
Isosorbide dinitrate in fixed combination with hydralazine hydrochloride: About 2 hours.336
Isosorbide mononitrate: About 5 hours.290 291 292
Stability
Storage
Oral (Isosorbide Dinitrate)
Tablets
Tight, light-resistant containers at room temperature (25°C); do not expose to extremes in temperature.b 302
Oral (Isosorbide Mononitrate)
Tablets (Extended-release and Conventional)
Conventional tablets (e.g., Monoket): Tight, light-resistant containers at 15–30°C.290 292 293
Oral (Isosorbide Dinitrate in Fixed Combination with Hydralazine Hydrochloride)
Tablets
Tight, light-resistant containers at 25°C; may be exposed to 15–30°C.336
Actions
-
The exact mechanism of action in the relief of angina pectoris has not been fully elucidated.c
-
Principal pharmacologic property is relaxation of vascular smooth muscle, resulting in generalized vasodilation.c
-
Peripheral venous resistance is decreased via a selective action on venous capacitance vessels and results in venous pooling of blood and decreased venous return to the heart.c
-
Vasodilatory effect on arteriolar resistance is not as great as the action on the venous side; as a result of this combined action, both venous filling pressure (preload) and, to a lesser extent, arterial impedance (afterload) are reduced.c
-
By decreasing myocardial oxygen consumption, nitrates and nitrites alter the imbalance of myocardial oxygen supply and consumption which is thought to cause angina pectoris.236 250
-
Because of their hemodynamic profile, particularly beneficial in patients with left ventricular systolic dysfunction or heart failure.236 250
-
Both direct vasodilatory effects on the coronary bed and drug-induced prevention of episodic coronary artery vasoconstriction increase total coronary blood flow.236
-
After therapeutic doses, cardiac output may increase transiently and then decrease.c
-
In addition to vascular smooth muscle, nitrates and nitrites relax bronchial, biliary (including the gallbladder, biliary ducts, and sphincter of Oddi), GI (including the esophagus), ureteral, and uterine smooth muscle; nitrates relax all smooth muscle irrespective of autonomic innervation and are functional antagonists of norepinephrine, acetylcholine, and histamine.c
Advice to Patients
-
Advise patients of the likelihood of headache, particularly with initial nitrate therapy.c Importance of consulting clinician if headache continues with repeated dosing.336
-
Advise patients to take nitrates as directed, particularly since tolerance can occur.c
-
Importance of instructing patients receiving isosorbide dinitrate for relief of acute attacks of angina pectoris to consult a clinician or go to a hospital emergency room immediately if chest pain is not relieved after 3 doses approximately every 5 minutes, because inability to relieve chest pain may indicate acute MI.c
-
Importance of informing patients receiving isosorbide dinitrate in fixed combination with hydralazine that inadequate fluid intake or excessive fluid loss due to diarrhea, vomiting, or perspiration may result in excessive hypotension, possibly leading to lightheadedness or syncope; if syncope occurs, discontinue treatment and notify clinician immediately.336
-
Importance of clinicians unfamiliar with their patients’ drug history, especially those involved in emergency care (e.g., for presumed myocardial infarction or ischemia), to take a careful history so that concomitant use with selective PDE inhibitors can be avoided.260 264 271
-
Importance of warning all patients receiving organic nitrates or nitrites about the potential interaction between the drugs and selective PDE inhibitors, even if they currently are not receiving the drugs, since there is substantial potential for patients to receive the drugs from another clinician, from a friend, with little or no clinical intervention (e.g., via the Internet),281 or illicitly.260 281 282
-
Importance of warning all patients taking either selective PDE inhibitors or organic nitrates or nitrites of the potentially severe and life-threatening hemodynamic consequences of taking the drugs within close proximity (e.g., within 24 hours of sildenafil; possibly more prolonged periods of risk with longer-acting PDE inhibitors) of taking a nitrate- or nitrite-containing preparation.260 282
-
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs as well as any concomitant illnesses.
-
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.
-
Importance of informing patients of other important precautionary information. (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
|
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
|---|---|---|---|---|
|
Oral |
Capsules, extended-release |
40 mg |
Dilatrate-SR |
Schwarz |
|
Tablets |
5 mg* |
Isordil Titradose (scored) |
Biovail |
|
|
Isosorbide Dinitrate Tablets |
||||
|
10 mg* |
Isosorbide Dinitrate Tablets |
|||
|
20 mg* |
Isosorbide Dinitrate Tablets |
|||
|
30 mg* |
Isosorbide Dinitrate Tablets |
|||
|
40 mg* |
Isordil Titradose (scored) |
Biovail |
||
|
Tablets, extended-release |
40 mg* |
Isosorbide Dinitrate Tablets ER |
||
|
Sublingual (Intrabuccal) |
Tablets |
2.5 mg* |
Isosorbide Dinitrate Tablets |
|
|
5 mg* |
Isosorbide Dinitrate Tablets |
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
|
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
|---|---|---|---|---|
|
Oral |
Tablets |
10 mg* |
Isosorbide Mononitrate Tablets |
|
|
Monoket (scored) |
Schwarz |
|||
|
20 mg* |
Isosorbide Mononitrate Tablets |
|||
|
Monoket (scored) |
Schwarz |
|||
|
Tablets, extended-release |
30 mg* |
Imdur (scored) |
Schering-Plough |
|
|
Isosorbide Mononitrate Tablets ER |
||||
|
60 mg* |
Imdur (scored) |
Schering-Plough |
||
|
Isosorbide Mononitrate Tablets ER |
||||
|
120 mg* |
Imdur |
Schering-Plough |
||
|
Isosorbide Mononitrate Tablets ER |
||||
|
Tablets, extended-release, film-coated |
20 mg |
Ismo |
ESP Pharma |
|
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
|---|---|---|---|---|
|
Oral |
Tablets, film-coated |
20 mg with Hydralazine Hydrochloride 37.5 mg |
BiDil (scored) |
NitroMed |
AHFS DI Essentials™. © Copyright 2024, Selected Revisions April 10, 2024. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.
References
Only references cited for selected revisions after 1984 are available electronically.
20. Assinder DF, Chasseaud LF, Taylor T. Plasma isosorbide dinitrate concentrations in human subjects after administration of standardizing and sustained-release formulations. J Pharm Sci. 1977; 66:775-8. http://www.ncbi.nlm.nih.gov/pubmed/577507?dopt=AbstractPlus
102. Whitworth CG, Grant WM. Use of nitrate and nitrite vasodilators by glaucomatous patients. Arch Ophthalmol. 1964; 71:492-6. http://www.ncbi.nlm.nih.gov/pubmed/14109031?dopt=AbstractPlus
103. Zah K. Vliv nitroglyceriner na krevni obeh u sitnici: X pokuane farmakologicka studie. Cesk Ofthalmol. 1957; 13:146-9.
104. Peczon JD, Grant WM, Lambert BW. Systemic vasodilators, intraocular pressure, and chamber depth in glaucoma. Am J Ophthalmol. 1971; 72:74-8. http://www.ncbi.nlm.nih.gov/pubmed/5571214?dopt=AbstractPlus
200. Wyeth Laboratories Inc. Isordil (isosorbide dinitrate) prescribing information. In: Physicians’ desk reference. 54th ed. Montvale NJ: Medical Economics Company Inc; 2000:3260-1.
201. Parker JO, Farrell B, Lahey KA et al. Effects of intervals between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med. 1987; 316:1440-4. http://www.ncbi.nlm.nih.gov/pubmed/3574424?dopt=AbstractPlus
202. Silber S, Krause KH, Theisen K. Nitrate-tolerance: dependence on dosage intervals? Circulation. 1984; 70(Suppl 2):II-289. Abstract No. 753.
203. Col J, Col-Debeys C, Lavenne-Pardonge E et al. Propylene glycol-induced heparin resistance during nitroglycerin infusion. Am Heart J. 1985; 110(1 Part 1):171-3. http://www.ncbi.nlm.nih.gov/pubmed/3925740?dopt=AbstractPlus
204. Habbab MA, Haft JI. Heparin resistance induced by intravenous nitroglycerin: a word of caution when both drugs are used concomitantly. Arch Intern Med. 1987; 147:857-60. http://www.ncbi.nlm.nih.gov/pubmed/3107486?dopt=AbstractPlus
205. Babka JC. Does nitroglycerin explode? N Engl J Med. 1983; 309:379. Letter.
206. Parke JD, Higgins SE. Hazards associated with chest application of nitroglycerin ointments. JAMA. 1982; 248:427. http://www.ncbi.nlm.nih.gov/pubmed/6806492?dopt=AbstractPlus
207. Kuhnen R, Nitsch J, Lüderitz B. Explosion von Nitropflastern bei Defibrillation. Dtsch Med Wochenschr. 1985; 110:37.
208. Marion Laboratories, Inc. Nitro-Bid Plateau CAPS (nitroglycerin) prescribing information. In: Huff BB, ed. Physicians’ desk reference. 51st ed. Montvale, NJ: Medical Economics Company Inc; 1997(Suppl A):A205-7.
209. Rorer Pharmaceuticals. Nitrospan (nitroglycerin) sustained-release capsules prescribing information. In: Huff BB, ed. Physicians’ desk reference. 42nd ed. Oradell, NJ: Medical Economics Company Inc; 1988:1807.
210. Summit Pharmaceuticals. Transderm-Nitro (nitroglycerin) transdermal prescribing information. Summit, NJ; 1996 May.
211. Geneva Generics. Nitroglycerin S.R. capsules prescribing information. Broomfield, CO; 1982 Aug.
212. Robertson D, Stevens RM. Nitrates and glaucoma. JAMA. 1977; 237:117. http://www.ncbi.nlm.nih.gov/pubmed/576138?dopt=AbstractPlus
213. Wizemann AJS, Wizemann V. Organic nitrate therapy in glaucoma. Am J Ophthalmol. 1980; 90:106-9. http://www.ncbi.nlm.nih.gov/pubmed/6772033?dopt=AbstractPlus
214. Sveska KJ. Nitrates may not be contraindicated in patients with glaucoma. Drug Intell Clin Pharm. 1985; 19:361.
215. Wisznia KI, Lazar M, Leopold IH. Oral isosorbide and intraocular pressure. Am J Ophthalmol. 1970; 70:630-4. http://www.ncbi.nlm.nih.gov/pubmed/4248312?dopt=AbstractPlus
216. American College of Cardiology and American Heart Association. ACC/AHA guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction). Circulation. 1990; 82:664-707. http://www.ncbi.nlm.nih.gov/pubmed/2197021?dopt=AbstractPlus
217. Jugdutt BI, Warnica JW. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications: effect of timing, dosage, and infarct location. Circulation. 1988; 78:906-19. http://www.ncbi.nlm.nih.gov/pubmed/3139326?dopt=AbstractPlus
218. Yusuf S, Collins R, McMahon S et al. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of randomized trials. Lancet. 1988; 1:1088-92. http://www.ncbi.nlm.nih.gov/pubmed/2896919?dopt=AbstractPlus
219. Sreebny LM, Valdini A. Xerostomia: a neglected symptom. Arch Intern Med. 1987; 147:1333-7. http://www.ncbi.nlm.nih.gov/pubmed/3300589?dopt=AbstractPlus
220. Rasler FE. Ineffectiveness of sublingual nitroglycerin in patients with dry mucous membranes. N Engl J Med. 1986; 314:181. http://www.ncbi.nlm.nih.gov/pubmed/3079881?dopt=AbstractPlus
221. Straehl P, Galeazzi RL. Isosorbide dinitrate bioavailability, kinetics, and metabolism. Clin Pharmacol Ther. 1985; 38:140-9. http://www.ncbi.nlm.nih.gov/pubmed/4017416?dopt=AbstractPlus
222. Thadani U, Whitsett T. Relationship of pharmacokinetic and pharmacodynamic properties of organic nitrates. Clin Pharmacokinet. 1988; 15:32-43. http://www.ncbi.nlm.nih.gov/pubmed/3135973?dopt=AbstractPlus
223. Bogaert MG. Clinical pharmacokinetics of organic nitrates. Clin Pharmacokinet. 1983; 8:410-21. http://www.ncbi.nlm.nih.gov/pubmed/6414751?dopt=AbstractPlus
224. Schwarz. Dilitrate-SR (isosorbide dinitrate) sustained release capsules prescribing information. Milwaukee, WI; 1998 Sep.
225. Sorbitrate (isosorbide dinitrate) prescribing information. In: Physicians’ desk reference. 54th ed. Montvale NJ: Medical Economics Company Inc; 2000:566-8.
226. Chasseaud LF, Darragh A, Doyle E et al. Isosorbide dinitrate plasma concentrations and bioavailability in human subjects after administration of standard oral and sublingual formulations. J Pharm Sci. 1984; 699-71.
227. Schaumann W. Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. Int J Clin Pharmacol Ther Toxicol. 1989; 27:445-53. http://www.ncbi.nlm.nih.gov/pubmed/2681004?dopt=AbstractPlus
228. Fung HL. Pharmacokinetics and pharmacodynamics of isosorbide dinitrate. Am Heart J. 1985; 110(1 Part 2):213-6. http://www.ncbi.nlm.nih.gov/pubmed/4013997?dopt=AbstractPlus
229. Taylor T, Chasseaud LF, Major RM et al. Bioequivalence of a sustained-release isosorbide dinitrate formulation at steady-state. Biopharm Drug Dispos. 1985; 6:119-29. http://www.ncbi.nlm.nih.gov/pubmed/4005392?dopt=AbstractPlus
230. Chasseaud LF, Doyle E, Taylor T et al. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations. Int J Clin Pharmacol Ther Toxicol. 1983; 21:514-8. http://www.ncbi.nlm.nih.gov/pubmed/6642789?dopt=AbstractPlus
231. Morrison RA, Wiegland UW, Jahnchen E et al. Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina. Clin Pharmacol Ther. 1983; 33:747-56. http://www.ncbi.nlm.nih.gov/pubmed/6851405?dopt=AbstractPlus
232. Smith D, Aldrich W, Dey M et al. A pharmacokinetic model for issorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate. Drug Metab Dispos. 1990; 18:429-34. http://www.ncbi.nlm.nih.gov/pubmed/1976063?dopt=AbstractPlus
233. Abshagen U, Betzien G, Endele R et al. Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration. Eur J Clin Pharmacol. 1985; 27:637-44. http://www.ncbi.nlm.nih.gov/pubmed/3987768?dopt=AbstractPlus
234. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993; 153:154-83. http://www.ncbi.nlm.nih.gov/pubmed/8422206?dopt=AbstractPlus
235. Warner Lambert. Nitrostat (nitroglycerin) tablets prescribing information. In: Physicians’ desk reference. 51st ed. Montvale, NJ: Medical Economics Company Inc; 1997:1981-2.
236. Ryan TJ, Antman EM, Brooks NH et al. ACC/AHA guidelines for the management of patients with acute myocardiac infarction: 1999 update: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardiac Infarction.) From website. 1996; 28:1328-428. http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards.aspx
237. Baxter Healthcare. Nitroglycerin in 5% dextrose injection prescribing information. Deerfield, IL; 1995 Jun.
238. 3M Pharmaceuticals. Minitran (nitroglycerin) transdermal delivery system prescribing information. Northridge, CA; 1995 Mar.
239. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Bethesda, MD: National Institutes of Health; 1997 Nov. (NIH publication No. 98-4080.)
240. Come PC, Pitt B. Nitroglycerin-induced severe hypotension and bradycardia in patients with acute myocardial infarction. Circulation. 1976; 54:624-8. http://www.ncbi.nlm.nih.gov/pubmed/822962?dopt=AbstractPlus
241. Kinch JW, Ryan TJ. Right ventricular infarction. N Engl J Med. 1994; 330:1211-7. http://www.ncbi.nlm.nih.gov/pubmed/8139631?dopt=AbstractPlus
242. Bussmann WD, Passek D, Seidel W et al. Reduction of CK and CK-MB indexes of infarct size by intravenous nitroglycerin. Circulation. 1981; 63:615-22. http://www.ncbi.nlm.nih.gov/pubmed/6780232?dopt=AbstractPlus
243. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994; 343:1115-22. http://www.ncbi.nlm.nih.gov/pubmed/7910229?dopt=AbstractPlus
244. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995; 345:669-85.
245. Becker RC, Corroa JM, Bovill EG et al. Intravenous nitroglycerin-induced heparin resistance: a qualitative antithrombin II abnormality. Am Heart J. 1990; 119:1254-61. http://www.ncbi.nlm.nih.gov/pubmed/2112878?dopt=AbstractPlus
246. Bode V, Welzel D, Franz G et al. Absence of drug interaction between heparin and nitroglycerin: randomized placebo-controlled cross-over study. Arch Intern Med. 1990; 150:2117-9. http://www.ncbi.nlm.nih.gov/pubmed/2121114?dopt=AbstractPlus
247. Gonzalez ER, Jones HD, Graham S et al. Assessment of the drug interaction between intravenous nitroglycerin and heparin. Ann Pharmacother. 1992; 26:1512-4. http://www.ncbi.nlm.nih.gov/pubmed/1482804?dopt=AbstractPlus
248. Fung HL, Chung SJ, Bauer JA et al. Biochemical mechanism of organic nitrtae action. Am J Cardiol. 1992; 70(Supp 5):4-10B.
249. Luscher TF. Endothelium-derived nitric oxide: the endogenous nitrovasodilator in th ehuman cardiovascular system. Eur Heart Journal. 1991; 12(Supp E):2-11.
250. Abrams J. Hemodynamic effects of nitroglycerin and long-acting nitrates. Am Heart J. 1985; 110:216-24. http://www.ncbi.nlm.nih.gov/pubmed/3925741?dopt=AbstractPlus
251. Winbury MM. Redistribution of left ventricular blood flow produced by nitroglycerin: an example of integration of the macro- and microcirculation. Circ Res. 1971; 28(Supp I):140-7.
252. Gorman MW, Sparks HV Jr. Nitroglycerin causes vasodilation within ischaemic myocardium. Cardiovasc Res. 1980; 14:515-21. http://www.ncbi.nlm.nih.gov/pubmed/6783307?dopt=AbstractPlus
253. Brown BG, Bolson E, Peterson RB et al. The mechanisms of nitroglycerin action: stenosis vasodilation as a major component of drug response. Circulation. 1981; 64:1089-97. http://www.ncbi.nlm.nih.gov/pubmed/6794931?dopt=AbstractPlus
254. Needleman P, Jakschik B, Johnson EM Jr. Sulfhydryl requirement for relaxation of vascular smooth muscle. J Pharmacol Exp Ther. 1973; 187:324-31. http://www.ncbi.nlm.nih.gov/pubmed/4201275?dopt=AbstractPlus
255. Cohn JN, Archibald DG, Ziesches S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986; 314:1547-52. http://www.ncbi.nlm.nih.gov/pubmed/3520315?dopt=AbstractPlus
256. Cohn JN, Johnson G, Ziesche et al. A comparison of enalapril with hydralazine—isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991; 325:303-10. http://www.ncbi.nlm.nih.gov/pubmed/2057035?dopt=AbstractPlus
257. Anon. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Part II. Management of heart failure: approaches to the prevention of heart failure. Am J Cardiol. 1999; 83:9A-38A.
258. Gibbons RJ, Chatterjee K, Daley J et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). J Am Coll Cardiol. 1999; 33:2092-7. http://www.ncbi.nlm.nih.gov/pubmed/10362225?dopt=AbstractPlus
259. Webb DJ, Freestone S, Allen MJ et al. Sildenafil citrate and blood-pressure-lowering drugs: Results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol. 1999; 83:21-8c. http://www.ncbi.nlm.nih.gov/pubmed/10073779?dopt=AbstractPlus
260. Cheitkin MD, Hutter AM, Brindis RG for the American College or Cardiology and American Heart Association. Technology and Practice Executive Committee [duplicate publication of Cheitkin MD, Hutter AM, Brindis RG for the American College or Cardiology and American Heart Association. ACC/AHA expert consensus document: use of sildenafil (viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol. 1999; 33:273-82.
261. Wallis RM, Corbin JD, Francis SH et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 1999; 83:3-12c.
262. Pfizer. Viagra (sildenafil citrate) prescribing information. New York, NY; 1999 June.
263. Zusman RM, Morales A, Glasser DB et al. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol. 1999; 83:35-44c.
264. Goldenberg MM. Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. Clin Ther. 1998; 20:1033-48. http://www.ncbi.nlm.nih.gov/pubmed/9916601?dopt=AbstractPlus
265. Nandwani R, Goutlay Y. Possible interaction between sildenafil and HIV combination therapy. Lancet. 1999; 353:840.
266. Anon. Summary of reports of death in Viagra users received from marketing (late March) through mid-November 1998. From FDA web site [no longer available online]. http://www.fda.gov
267. Aldridge J, Measham F. Sildenafil (Viagra) is used as a recreational drug in England. BMJ. 1999; 318:669. http://www.ncbi.nlm.nih.gov/pubmed/10066221?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1115104&blobtype=pdf
268. Anon. How to buy almost any drug without a prescription: 1000 Mexican pharmacy contacts - 450 Caribbean pharmacies. From the Drugquest Web Site/doorway.htm) [no longer available online]. https://www.drugquest.com/doorway.htm)
269. Anon. Prescription free pharmaceuticals by e-mail at incredibly low prices. From the Vitality Health Products Web Site [no longer available online]. https://www.vitality3.net)
270. Anon. Viagra. From the 4nRx Web Site. https://www.4nrx.com)
271. Pfizer. Dear doctor letter to emergency physicians regarding Viagra contraindication: concomitant administration of an organic nitrate. From FDA web site [no longer available online]. 1998 May 22. http://www.fda.gov
272. Kloner RA. Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol. 1999; 83:576-82. http://www.ncbi.nlm.nih.gov/pubmed/10073864?dopt=AbstractPlus
273. Pfizer, New York, NY. Personal communication on sildenafil.
274. Steers WD. Viagra-after one year. Urology. 1999; 54:12-7. http://www.ncbi.nlm.nih.gov/pubmed/10414719?dopt=AbstractPlus
275. Langtry HD, Markham A. Sildenafil: a review of its use in erectile dysfunction. Drugs. 1999; 57:967-89. http://www.ncbi.nlm.nih.gov/pubmed/10400408?dopt=AbstractPlus
276. Agency for Health Care Policy and Research. Diagnosing and managing unstable angina. 1994. (AHCPR publication no. 94-0603)
277. Théroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation. 1997; 97:1195-206.
278. Tonkin AM, Aroney CN. Guidelines for managing patients with unstable angina: rating the evidence and rationale for treatment. Med J Aust. 1997; 16:644-7.
279. Zaacks SM, Liebson PR, Calvin JE et al. Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications? J Am Coll Cardiol. 1999; 33:107-18.
280. Cairns J, Théroux P, Armstrong P et al. Unstable angina—Report from a Canadian expert round table. Can J Cardiol. 1996; 12:1279-92. http://www.ncbi.nlm.nih.gov/pubmed/8987969?dopt=AbstractPlus
281. Armstrong K, Schwartz JS, Asch DA. Direct sale of sildenafil (Viagra) to consumers over the Internet. N Engl J Med. 1999; 341:1389-92. http://www.ncbi.nlm.nih.gov/pubmed/10536133?dopt=AbstractPlus
282. Arora RR, Meilli L. Acute myocardial infarction after the use of sildenafil. N Engl J Med. 1999; 341:700.
283. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology. 1999; 91:307-10. http://www.ncbi.nlm.nih.gov/pubmed/10422958?dopt=AbstractPlus
284. Goldstein I, Lue TF, Padma-Nathan H et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998; 338:1397-404. http://www.ncbi.nlm.nih.gov/pubmed/9580646?dopt=AbstractPlus
285. Anon. Sildenafil: an oral drug for impotence. Med Lett Drugs Ther. 1998; 40:51-52. http://www.ncbi.nlm.nih.gov/pubmed/9599594?dopt=AbstractPlus
286. Reviewers’ comments (personal observations) on sildenafil.
287. Kloner RA, Zusman RM. Cardiovascular effects of sildenafil citrate and recommendations for its use. Am J Cardiol. 1999; 84:11-7N.
288. Padma-Nathan H. A new era in the treatment of erectile dysfunction. Am J Cardiol. 1999; 84:18-23N. http://www.ncbi.nlm.nih.gov/pubmed/10404845?dopt=AbstractPlus
289. Heart and Stroke Foundation of Canada and Canadian Cardiovascular Society. A statement on the use of sildenafil in the management of sexual dysfunction in patients with cardiovascular disease. Can J Cardiol. 1999; 15:396-9. http://www.ncbi.nlm.nih.gov/pubmed/10348610?dopt=AbstractPlus
290. Wyeth-Ayerst. Ismo (isosorbide mononitrate) tablets prescribing information. In: Physicians’ desk reference. 54th ed. Montvale, NJ: Medical Economics Company Inc; 2000:3258-60.
291. Schwarz. Monoket (isosorbide mononitrate) tablets prescribing information (dated 1999 Jul). Milwaukee, WI; 1999 Jul.
292. Key Pharmaceuticals. Imdur (isosorbide mononitrate) extended-release tablets prescribing information (dated 1998 Sept). In: Physicians’ desk reference. 54th ed. Montvale, NJ: Medical Economics Company Inc; 2000:1467-9.
293. USP DI: drug information for the health care provider. Johnson KW, ed. 20th ed. Englewood, CO: Micromedex, Inc; 2000:2269-70.
294. Parfitt K, ed. Martindale: the complete drug reference. 32nd ed. London, UK: The Pharmaceutical Press; 1999:893-4.
295. Nyberg G, Blychert LO, Jonsson UE. Pharmacokinetics of isosorbide-5-mononitrate in a controlled-release (Durules) formulation. Br J Clinical Pharmacol. 1985; 20:541P.
296. Kampmann JP. Pharmacokinetics of various preparations of organic nitrates. Drugs. 1987; 33(Suppl 4):5-8. http://www.ncbi.nlm.nih.gov/pubmed/3113910?dopt=AbstractPlus
297. Jonsson UE. Various administration forms of nitrates and their possibilities. Drugs. 1987; 33(Suppl 4):23-31. http://www.ncbi.nlm.nih.gov/pubmed/3304960?dopt=AbstractPlus
298. Gunasekara NS, Noble S. Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris. Drugs. 1999; 57:261-77. http://www.ncbi.nlm.nih.gov/pubmed/10188765?dopt=AbstractPlus
299. Laufen H, Leitold M. The effect of food on the oral absorption of isosorbide-5-mononitrate. Br J Clin Pharmacol. 1984; 18:967-8. http://www.ncbi.nlm.nih.gov/pubmed/6529537?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1463671&blobtype=pdf
300. Kosoglou T, Kazierad DJ, Schentag JJ et al. Effect of food on the oral bioavailability of isosorbide-5-mononitrate administered as an extended-release tablet. J Clin Pharmacol. 1995; 35:151-8. http://www.ncbi.nlm.nih.gov/pubmed/7751425?dopt=AbstractPlus
301. Thomson AH, Miller SHK, Green ST et al. The effect of food on the absorption of slow-release isosorbide-5-mononitrate tablets. Eur J Clin Pharmacol. 1988; 34:47-50. http://www.ncbi.nlm.nih.gov/pubmed/3360048?dopt=AbstractPlus
302. Wyeth-Ayerst. Isordil Titradose (isosorbide dinitrate) tablets prescribing information. In: Physicians’ desk reference. 54th ed. Montvale, NJ: Medical Economics Company Inc; 2000:3261-2.
303. Kirsten R, Nelson K, Kirsten D et al. Clinical pharmacokinetics of vasodilators: part II. Clin Pharmacokinet. 1998; 35:9-36. http://www.ncbi.nlm.nih.gov/pubmed/9673832?dopt=AbstractPlus
304. Wagner F, Siefert F, Trenk D et al. Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate. Eur J Clin Pharmacol. 1990; 38(Suppl 1):S53-9. http://www.ncbi.nlm.nih.gov/pubmed/2354713?dopt=AbstractPlus
305. Waller DG. Optimal nitrate therapy with a once-daily sustained-release formulation of isosorbide mononitrate. J Cardiovasc Pharmacol. 1999; 34(Suppl 2):S21-7. http://www.ncbi.nlm.nih.gov/pubmed/10499557?dopt=AbstractPlus
306. Kinlay S, Wall RC, Page JH et al. Effect of wetting the mouth on aortic blood pressure just before taking sublingual nitrates. Am J Cardiol. 1996; 78:555-8. http://www.ncbi.nlm.nih.gov/pubmed/8806342?dopt=AbstractPlus
307. Jonsson UE. Development of long-acting nitrate delivery systems. Eur J Clin Pharmacol. 1990; 38(Suppl 1):S15-9. http://www.ncbi.nlm.nih.gov/pubmed/2113000?dopt=AbstractPlus
308. Key Pharmaceuticals, Kenilworth, NJ. Personal communication on Imdur.
309. Prakash A, Markham A. Long-acting isosorbide mononitrate. Drugs. 1999; 57:93-9. http://www.ncbi.nlm.nih.gov/pubmed/9951954?dopt=AbstractPlus
310. Vogt D, Trenk D, Bonn R et al. Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration. Eur J Clin Pharmacol. 1994; 46:319-24. http://www.ncbi.nlm.nih.gov/pubmed/7957516?dopt=AbstractPlus
311. Taylor T, Chasseaud LF, Doyle E et al. Isosorbide dinitrate pharmacokinetics. Arzneim Forsch. 1982; 32:1329-33.
312. Taylor IW, Major RM, Chasseaud LF et al. Saliva concentrations of isosorbide dinitrate, isosorbide-2-mononitrate and isosorbide-5-mononitrate. Br J Clin Pharmacol. 1984; 17:585-7. http://www.ncbi.nlm.nih.gov/pubmed/6733004?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1463459&blobtype=pdf
313. Udhoji VN, Heng MK. Hemodynamic effects of high-dose sustained-action oral isosorbide dinitrate in stable angina. Am J Med. 1984; 76:234-40. http://www.ncbi.nlm.nih.gov/pubmed/6364805?dopt=AbstractPlus
314. Trenk D, Hinder M, Stengele E et al. Comparison of the initial hemodynamic effects of immediate-release versus sustained-release isosorbide-5-mononitrate following single oral doses. J Clin Pharmacol. 2000; 40:168-76. http://www.ncbi.nlm.nih.gov/pubmed/10664923?dopt=AbstractPlus
315. Evers J, Bonn R, Boertz A et al. Pharmacokinetics of isosorbide-5-nitrate during hemodialysis and peritoneal dialysis. Eur J Clin Pharmacol. 1987; 32:503-5. http://www.ncbi.nlm.nih.gov/pubmed/3622599?dopt=AbstractPlus
316. Ergotamine (Ergostat) interactions: Nitroglycerin. In: Hansten PD, Horn JR. Drug interactions & updates. Vancouver, WA: Applied Therapeutics; 1997:263.
317. Rutherford JD. Nitrate tolerance in angina therapy: how to avoid it. Drugs. 1995; 49:196-9. http://www.ncbi.nlm.nih.gov/pubmed/7729327?dopt=AbstractPlus
318. Abrams J, Elkayam U, Thadani U et al. Tolerance: an historical overview. Am J Cardiol. 1998; 81(Suppl 1A):3-14A.
319. Glasser SP. Clinical mechanisms of nitrate action. Am J Cardiol. 1998; 81(1A):49-53A.
320. Loscalzo J. Antiplatelet and antithrombotic effects of organic nitrates. Am J Cardiol. 1992; 70:18-22B.
321. Parke-Davis. Nitrostat (nitroglycerin) tablets prescribing information. In: Physicians’ desk reference. 54th ed. Montvale, NJ: Medical Economics Company Inc; 2000:2271-2.
322. Raehl CL, Nolan PE. Ischemic heart disease: anginal syndromes. In: Young LY, Koda-Kimble MA, eds. Applied therapeutics: the clinical use of drugs. 6th ed. Vancouver, WA: Applied Therapeutics, Inc; 1995:13-6-13-11.
323. Flaherty JT. Nitrate tolerance: a review of the evidence. Drugs. 1989; 37:523-50. http://www.ncbi.nlm.nih.gov/pubmed/2661197?dopt=AbstractPlus
324. Raehl CL, Nolan PE. Ischemic heart disease: anginal syndromes. In: Koda-Kimble MA, Young LY, eds. Applied therapeutics: the clinical use of drugs. 6th ed. Vancouver, WA: Applied Therapeutics, Inc; 1995:13-1-25.
325. ISMO (isosorbide mononitrate) tablets. In: MedWatch: summary of safety-related drug labeling changes approved by FDA. Rockville, MD: US Food and Drug Administration; 1999 Jun.
326. Forest Pharmaceuticals. Nitrogard (Nitroglycerin extended-release) buccal tablets prescribing informtion. St. Louis, MO; 1991 Mar.
327. Eon Laboratories. Nitroglycerin slowcaps (nitroglycerin sustained-release) capsules prescribing information. Laurelton, NY; 2000 Mar.
329. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993; 153:154-83. http://www.ncbi.nlm.nih.gov/pubmed/8422206?dopt=AbstractPlus
331. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Bethesda, MD: National Institutes of Health; 1997 Nov. (NIH publication No. 98-4080.)
332. Bayer Health Care. Levitra (vardenafil) tablets prescribing information. West Haven, CT; 2003 Aug.
333. Lilly ICOS LLC. Cialis (tadalafil) tablets prescribing information. Indianapolis, IN; 2003 Nov.
334. Kloner RA, Hutter AM, Emmick JT et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol. 2003; 42:1855-60. http://www.ncbi.nlm.nih.gov/pubmed/14642699?dopt=AbstractPlus
335. Coleman CI, Carabino JM, Vergara CM et al. Vardenafil: an oral selective phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Formulary. 2003; 38:131-48.
336. NitroMed, Inc. BiDil (isosorbide dinitrate and hydralazine hydrochloride) tablets prescribing information. Lexington, MA; 2005 Jun 23.
337. Taylor AL, Ziesche S, Yancy C et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004; 351:2049-57. http://www.ncbi.nlm.nih.gov/pubmed/15533851?dopt=AbstractPlus
338. Anon. BiDil for heart failure. Med Lett Drugs Ther. 2005; 47:77-8.
339. The American Heart Association. Guidelines 2005 for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2005; 112(Suppl I):IV1-211.
500. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Bethesda, MD: National Institutes of Health; 2004 Aug. (NIH publication No. 04-5230.)
502. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31:1281-357. http://www.ncbi.nlm.nih.gov/pubmed/23817082?dopt=AbstractPlus
524. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128:e240-327.
542. Marik PE, Varon J. Hypertensive crises: challenges and management. Chest. 2007; 131:1949-62. http://www.ncbi.nlm.nih.gov/pubmed/17565029?dopt=AbstractPlus
700. Yancy CW, Jessup M, Bozkurt B et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016; :.
701. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; :. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4946749&blobtype=pdf
703. Ansara AJ, Kolanczyk DM, Koehler JM. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck. J Clin Pharm Ther. 2016; 41:119-27. http://www.ncbi.nlm.nih.gov/pubmed/26992459?dopt=AbstractPlus
b. AHFS drug information 2004. McEvoy GK, ed. Isosorbide dinitrate and isosorbide mononitrate. American Society of Health-System Pharmacists; 2004:1685-87.
c. AHFS drug information 2004. McEvoy GK, ed. Nitrates and nitrites general statement. American Society of Health-System Pharmacists; 2004:1679-84.
PDH. Schilling McCann JA, Publisher. Pharmacists drug handbook. 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins and American Society of Health-System Pharmacists; 2003.